United Kingdomworldobesity.org
Also known as International Association for the Study of Obesity and IASO.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
